Meeting
2021 ASCO Annual Meeting
Pancreatic volumes in immune checkpoint inhibitor-induced diabetes.
Authors
Rebecca Jeun
Baylor College of Medicine, Houston, TX
Rebecca Jeun , Sireesha Yedururi , Victor Lavis , Conor Best , Jeena Varghese , Ramona Dadu , Isabella Claudia Glitza , Sonali Thosani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2644)
DOI
10.1200/JCO.2021.39.15_suppl.2644
Abstract #
2644
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu
Poster
2016 ASCO Annual Meeting
Tumor- and class-specific patterns of immune-related adverse events (irAEs) of immune checkpoint inhibitors (ICIs): A systematic review (SR).
First Author: Daphne Day
Poster
2024 ASCO Annual Meeting
Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma.
First Author: Ghassan K. Abou-Alfa
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Role of proton pump inhibitors in immune checkpoint inhibitor colitis.
First Author: Roshini Pradeep